Benzydamine for the prevention of pharyngo-laryngeal pathology following tracheal intubation.
A clinical study was carried out to assess the antiinflammatory effectiveness and related properties of this drug. It was performed double-blind in 40 adult patients (ASA I, and II) undergoing major otorhinolaryngological surgical procedures with tracheal intubation. The patients received benzydamine at random (n = 20), or a similar solution without the active substance (n = 20). The following parameters were considered: physical examination, sensations referred from patient, cytologic examination, glottographic examination, and spectrographic examination. The results suggest that benzydamine applied locally at a concentration of 0.3% has therapeutic efficacy without local or systemic side-effects.
D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D001591:Benzydamine / Q000627:therapeutic use*; D003680:Deglutition Disorders / Q000209:etiology / Q000517:prevention & control*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007442:Intubation, Intratracheal / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D010612:Pharyngitis / Q000209:etiology / Q000517:prevention & control*; D011292:Premedication; D011720:Pyrazoles / Q000627:therapeutic use*; D011897:Random Allocation
D011720:Pyrazoles; D001591:Benzydamine